Vertex Pharmaceuticals Stock Price on July 25, 2024
| VRTX Stock | USD 498.73 11.48 2.36% |
Below is the normalized historical share price chart for Vertex Pharmaceuticals extending back to July 24, 1991. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Vertex Pharmaceuticals stands at 498.73, as last reported on the 18th of October 2024, with the highest price reaching 499.09 and the lowest price hitting 487.96 during the day.
If you're considering investing in Vertex Stock, it is important to understand the factors that can impact its price. At this stage we consider Vertex Stock to be very steady. Vertex Pharmaceuticals owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0134, which indicates the firm had a 0.0134% return per unit of risk over the last 3 months. We have found thirty technical indicators for Vertex Pharmaceuticals, which you can use to evaluate the volatility of the company. Please validate Vertex Pharmaceuticals' Risk Adjusted Performance of 0.0285, coefficient of variation of 3288.78, and Semi Deviation of 1.59 to confirm if the risk estimate we provide is consistent with the expected return of 0.0182%.
At this time, Vertex Pharmaceuticals' Total Stockholder Equity is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 23.9 B in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 153.1 M in 2024. . At this time, Vertex Pharmaceuticals' Price Earnings Ratio is fairly stable compared to the past year. Price Book Value Ratio is likely to rise to 7.46 in 2024, whereas Price To Sales Ratio is likely to drop 10.12 in 2024. Vertex Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 24th of July 1991 | 200 Day MA 447.969 | 50 Day MA 474.3228 | Beta 0.402 |
Vertex |
Sharpe Ratio = 0.0134
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VRTX |
Estimated Market Risk
| 1.36 actual daily | 12 88% of assets are more volatile |
Expected Return
| 0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 1 99% of assets perform better |
Based on monthly moving average Vertex Pharmaceuticals is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vertex Pharmaceuticals by adding it to a well-diversified portfolio.
Price Book 8.5119 | Enterprise Value Ebitda 259.9402 | Price Sales 12.4522 | Shares Float 257.3 M | Wall Street Target Price 512.16 |
Related Headline
Sarepta Therapeutics Headline on 25th of July 2024
Disposition of 11723 shares by Dallan Murray of Sarepta Ther... by Dallan Murray
Filed transaction by Sarepta Therapeutics Officer: Chief Customer Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Vertex Pharmaceuticals Valuation on July 25, 2024
It is possible to determine the worth of Vertex Pharmaceuticals on a given historical date. On July 25, 2024 Vertex was worth 494.0 at the beginning of the trading date compared to the closed value of 492.26. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Vertex Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Vertex Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Vertex Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Vertex Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 488.46 | 491.99 | 486.25 | 490.80 | 965,631 | |
07/25/2024 | 494.00 | 503.99 | 490.70 | 492.26 | 985,118 |
| 493.14 | 502.97 | 492.17 | 495.26 | 773,800 |
| Backtest Vertex Pharmaceuticals | | | Vertex Pharmaceuticals History | | | Vertex Pharmaceuticals Valuation | Previous | Next |
Vertex Pharmaceuticals Trading Date Momentum on July 25, 2024
| On July 26 2024 Vertex Pharmaceuticals was traded for 495.26 at the closing time. The top price for the day was 502.97 and the lowest listed price was 492.17 . The trading volume for the day was 773.8 K. The trading history from July 26, 2024 was a factor to the next trading day price jump. The trading price change against the next closing price was 0.61% . The trading price change against the current closing price is 4.49% . |
Vertex Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Vertex Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Vertex financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Vertex Pharmaceuticals Stock history
Vertex Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Vertex is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Vertex Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Vertex Pharmaceuticals stock prices may prove useful in developing a viable investing in Vertex Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 260.5 M | 153.1 M | |
| Net Income Applicable To Common Shares | 3.8 B | 4 B |
Vertex Pharmaceuticals Quarterly Net Working Capital |
|
Vertex Pharmaceuticals Stock Technical Analysis
Vertex Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Vertex Pharmaceuticals Period Price Range
Low | October 18, 2024
| High |
0.00 | 0.00 |
Vertex Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Vertex Pharmaceuticals October 18, 2024 Market Strength
Market strength indicators help investors to evaluate how Vertex Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Vertex Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Vertex Pharmaceuticals stock market strength indicators, traders can identify Vertex Pharmaceuticals entry and exit signals to maximize returns
Vertex Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Vertex Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Vertex Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Vertex to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0285 | |||
| Jensen Alpha | (0.02) | |||
| Total Risk Alpha | (0.08) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0372 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.